Brazil To Break Patent On Abbott Drug In Ten Days

Law360, New York (July 1, 2005, 12:00 AM EDT) -- Brazil has informed Abbott Laboratories that it will break the company's patent on the antiretroviral drug Kaletra in the next few days unless the U.S. drug maker offers a steep price break on the HIV/AIDS drug.

Brazilian Health Minister Humberto Costa said the government would break the patent within 10 days unless the company lowers the price of the drug 42% to $1.17 per pill, according to the Financial Rimes.

If the patent is broken, generic drug manufacturers could begin producing versions of the drug, which...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.